Business Context and Reporting Period
Company: Inotiv, Inc. (NOTV)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended December 31, 2025 (Fiscal Q1 2026)
Business Overview: Inotiv is a leading contract research organization (CRO) providing nonclinical and analytical drug discovery services (Discovery and Safety Assessment segment) and selling research-quality animals and diets (Research Models and Services segment). The company operates globally with significant presence in the United States and Netherlands.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $120,879 | $119,876 |
| Operating Loss | $(16,330) | $(15,507) |
| Consolidated Net Loss | $(28,378) | $(27,630) |
| Loss Per Share (Basic & Diluted) | $(0.83) | $(1.02) |
| Cash and Cash Equivalents (End of Period) | $12,732 | $38,043 |
| Net Cash Used in Operating Activities | $(5,433) | $(4,497) |
| Total Debt (Current Portion) | $405,773 | N/A |
| Revolving Credit Facility Outstanding | $6,000 | N/A |
Note: Total debt is classified as current due to anticipated covenant non-compliance and maturity dates within 12 months.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 0.8% to $120.9 million. This was driven by a 12.0% increase in the Discovery and Safety Assessment (DSA) segment ($47.9M), partially offset by a 5.4% decline in the Research Models and Services (RMS) segment ($72.9M) due to lower non-human primate (NHP) volumes.
- Profitability: Operating loss widened slightly to $16.3 million. DSA operating income improved to $3.1 million (up 61.8% YoY), while RMS operating loss expanded to $3.6 million (up 199.9% YoY) due to revenue declines and increased operating expenses.
- Liquidity: Cash and cash equivalents decreased by $9.0 million to $12.7 million, primarily due to negative operating cash flows and capital expenditures of $5.2 million.
- Debt Classification: The company reclassified all long-term debt (Term Loans, Convertible Notes, Second Lien Notes) as current liabilities because management forecasts noncompliance with financial covenants within the next 12 months.
Guidance, Outlook, Risks, and Unusual Items
Going Concern and Liquidity Risks
The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern. Management forecasts noncompliance with financial covenants (First Lien Leverage Ratio and Fixed Charge Coverage Ratio) for the remainder of fiscal 2026. While an Eighth Amendment to the Credit Agreement waived covenants for Q1 2026, it increased the minimum liquidity requirement to $30 million starting March 6, 2026. The company's major debt facilities mature in November 2026.
Unusual Items and Contingencies
- Legal Settlements: The company recorded an $11 million liability and a corresponding $11 million insurance recovery asset related to the settlement of a securities class action and derivative lawsuits. The cash settlement of $8.75 million was fully funded by insurance.
- Cybersecurity Incident: An August 2025 cybersecurity incident resulted in unauthorized access to systems. The company recorded a $5.45 million insurance recovery receivable related to this incident.
- Government Resolution: The company is subject to a Resolution Agreement and Plea Agreement with the DOJ regarding a former canine breeding facility, requiring fines totaling $22 million and a compliance monitor through 2030.
- Nasdaq Delisting Notice: The company received notice of non-compliance with the Nasdaq Minimum Bid Price Rule ($1.00 per share) as of December 31, 2025. It has 180 days to regain compliance or risk delisting.
- Tariffs: Imported NHPs are subject to tariffs of 15-20%, negatively impacting cash flows.
Management Commentary
Management plans to optimize capital allocation, focus on margin discipline, and increase DSA contract awards. They are exploring debt refinancing alternatives but noted no assurance that lenders will agree to amendments or that additional capital can be raised.
Investor Verification Checklist
- Covenant Compliance: Verify the company's ability to meet the new $30 million minimum liquidity covenant effective March 6, 2026, given current cash levels of $12.7 million.
- Debt Maturity: Assess the feasibility of refinancing or repaying approximately $406 million in debt maturing in November 2026.
- Going Concern Status: Monitor subsequent filings for updates on the "substantial doubt" disclosure and any additional waivers or amendments to the Credit Agreement.
- Nasdaq Listing: Track the stock price to determine if the company can regain compliance with the $1.00 minimum bid price rule or if a reverse stock split is required.
- Legal Finalization: Confirm final court approval of the derivative lawsuit settlement and the finalization of the cybersecurity incident costs.